# Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

> **NCT01498874** · PHASE2 · COMPLETED · sponsor: **XOMA (US) LLC** · enrollment: 127 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Placebo
- **DRUG:** gevokizumab
- **DRUG:** gevokizumab

## Key facts

- **NCT ID:** NCT01498874
- **Lead sponsor:** XOMA (US) LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-04
- **Final completion:** 2013-06
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2014-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01498874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01498874, "Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01498874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*